Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
Metagenomi Therapeutics, Inc. (MGX) had Operating Cash Flow per Share of $-2.39 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$25.21M |
|
$-87.87M |
|
-- |
|
$25.21M |
|
$121.22M |
|
$-96.01M |
|
$8.09M |
|
$-87.93M |
|
$-87.93M |
|
$-87.87M |
|
$-87.87M |
|
$-87.87M |
|
$-87.87M |
|
$-96.01M |
|
$-93.91M |
|
37.25M |
|
37.25M |
|
$-2.36 |
|
$-2.36 |
|
| Balance Sheet Financials | |
$165.54M |
|
$12.29M |
|
$55.56M |
|
$221.10M |
|
$22.93M |
|
-- |
|
$39.57M |
|
$62.51M |
|
$158.60M |
|
$158.60M |
|
$158.60M |
|
37.62M |
|
| Cash Flow Statement Financials | |
$-88.89M |
|
$103.53M |
|
$-0.36M |
|
$32.63M |
|
$46.91M |
|
$14.28M |
|
$11.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.22 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-380.85% |
|
-380.85% |
|
-372.50% |
|
-348.77% |
|
-348.54% |
|
$-89.43M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
-- |
|
82.66 |
|
4.42 |
|
-55.40% |
|
-55.40% |
|
-39.74% |
|
-55.40% |
|
$4.22 |
|
$-2.40 |
|
|
Operating Cash Flow per Share |
$-2.39 |